Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.
Journal article published in 2017 by
Rebecca J. Lee,
Gabriela Gremel,
A. Marshall,
K. A. Myers,
N. Fisher,
J. A. Dunn,
Nathalie Dhomen 
,
P. G. Corrie,
M. R. Middleton,
Paul C. Lorigan,
Richard Marais
,
P. G. Corrie,
M. R. Middleton,
Paul C. Lorigan,
Richard Marais
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma.